

For Health Professionals Who Care for Cancer Patients

Inside This Issue:

Editor's Choice

Learn About Bispecifics!, GI Protocol Optimization

Cancer Drug Manual®

New: Epcoritamab **Revised:** Dexamethasone, enzalutamide, irinotecan, ponatinib, tislelizumab
Chemotherapy Preparation and Stability Chart:
Epcoritamab

NEW Protocols, PPPOs and Patient Handouts

GU GUMCSPENZ

REVISED Protocols, PPPOs and Patient Handouts

BR UBRAJABEI, UBRAJABET, BRAJLDTAM, BRAVLRHT, BRAJTAM, BRAVLRHT, BRAVTAM | **CN** CNETO | **GO** GOOVFOLAM, GOOVOLAPM | **GU** UGUNMPENZ, UGUPENZ | **LK** ULKCMLP | **LY** LYCODOXMR, LYIT | **MY** MYDARLD, MYDARLDF | **SM** SMAVDAB, SMAVDT, SMAVEB, SMAVVC, SMAVVEM | **SC** SCICANS

Resources and Contact Information

Editor's Choice

Learn About Bispecifics!

Dr. Alina Gerrie, hematologist, Center for Lymphoid Cancer – BC Cancer, will be hosting a virtual education session on bispecific T-cell engager antibody treatments on June 18th at 12pm.

If interested, join by clicking the following link:

<https://phsa.zoom.us/j/64134381659?pwd=VuZRq0NBT2oonoZPMABreJqvHI1h56.1>

GI Protocol Optimization

The Gastrointestinal (GI) Tumour Group will be launching a series of revisions to existing GI treatment regimens, for optimization and consistency across protocols. These revisions will be implemented in a phased approach over the next several months. Notable changes for July and August will include minor eligibility updates, simplification, and alignment of protocol testing requirements. To streamline protocols, mandatory testing of calcium and magnesium in oxaliplatin-containing protocols will be removed.

All documents are available in the [Cancer Drug Manual[®]](#) on the BC Cancer website.

New Documents

Note that the following drug is not a BC Cancer Benefit Drug and requires application to the BC Cancer Compassionate Access Program (CAP). The corresponding Interim Monograph, Patient Handout and Chemotherapy Preparation and Stability Chart entry is made available for reference only.

The **Epcoritamab Interim Monograph** has been expanded and a **Patient Handout** has been developed. Expert review was provided by Dr. Alina Gerrie (Hematologist/oncologist, BC Cancer Lymphoma Tumour Group) and Jelena Mucovic (Oncology Drug Information Specialist, BC Cancer Provincial Pharmacy). All monograph sections have been reviewed and updated. The following sections have been added or expanded: *Pharmacokinetics, Special Precautions, Side Effects, Interactions, and Dosage Guidelines*.

Epcoritamab is a bispecific T-cell engager that targets T cell antigen CD3 expressed and B cell antigen CD20 on malignant cells. Epcoritamab is used in the treatment of B-cell lymphoma. Dosing follows a weekly step-up dosing regimen for the first cycle, with dose increments given on days 1, 8, 15, and 22. Thereafter, epcoritamab is given as a fixed dose of 48 mg. Cycle length is 4 weeks. The interval between doses changes with subsequent cycles, going from weekly to twice weekly to monthly over time.

Highlights from these documents include:

- Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) have been reported with epcoritamab; refer to BC Cancer [SCCRS](#) and [SCICANS](#) protocols
- Premedication with corticosteroid, antihistamine, and antipyretic is recommended prior to all step-up doses (cycle 1) to reduce the risk of CRS
- Antimicrobial/antiviral prophylaxis may be required to prevent reactivation of infections such as herpes zoster

Epcoritamab has been added to the **Chemotherapy Preparation and Stability Chart**, and the **BC Health Authorities Provincial Hazardous Drug List**.

Revised Documents

Dexrazoxane Chemotherapy Preparation and Stability Chart

Product column: clarified that drug to be diluted in an empty infusion bag with lactated ringers to recommended final concentration

Enzalutamide Patient Handout

Side effect table: added high blood pressure

Irinotecan Monograph and Patient Handout

Special Precautions: updated *Cautions, Carcinogenicity, Fertility, Pregnancy, and Breastfeeding*

Side Effects table: updated emetogenicity per SCNAUSEA and current NCCN Guidelines

Side Effects paragraph: updated *Insomnia and dizziness* paragraph

Interactions: updated table (minor wording changes) and paragraphs after the table (edited for conciseness)

Supply and Storage: updated with current Canadian brands

Parenteral Administration: updated references for BC Cancer standard administration

Cancer Drug Manual[©]

Dosage Guidelines: updated all sections, including dosing in hepatic failure, Gilbert's syndrome, and diarrhea

Patient Handout: updated style and formatting throughout as per current template design

Ponatinib Monograph and Patient Handout

Supply and Storage: deleted information pertaining to the Controlled Distribution Program as this program has ended

Patient Handout: updated throughout per current template language

Tislelizumab Chemotherapy Preparation and Stability Chart

Drug & Strength: added protect from light per new product information

Product: revised recommended final concentration

Special precautions: added discard instructions and recommendation regarding in-line filters

Continuing Education

Family Practice Oncology Network Continuing Medical Education

The Family Practice Oncology Network (FPON) is pleased to announce a webinar session on '**Advanced Melanoma: Current Management and Follow-Up Care**' on Thursday, 20 June 2024, from 8 am to 9 am, as part of the Complimentary Accredited Webinar Series. The advanced melanoma session will cover:

- Current management
- Current prognosis
- Melanoma follow-up care recommendations

For more information and links to registration, visit:

<https://ubccpd.ca/learn/learning-activities/course?eventtemplate=764>

List of Revised Protocols, Pre-Printed Orders and Patient Handouts

BC Cancer Protocol Summaries, Provincial Pre-Printed orders (PPPOs) and Patient Handouts are revised periodically. New, revised or deleted protocols, PPPOs and patient handouts for this month are listed below, with document revisions indicated in the respective columns. Protocol codes for treatment requiring BC Cancer Compassionate Access Program approval are prefixed with the letter **U**.

NEW Protocols, PPPOs and Patient Handouts (new documents checked)

Code	Protocol Title	Protocol	PPPO	Handout
GUMCSPENZ	Palliative Therapy for Metastatic Castration Sensitive Prostate Cancer Using Enzalutamide	--	--	<input checked="" type="checkbox"/>

REVISED Protocols, PPPOs and Patient Handouts (*revisions in respective columns*)

Code	Protocol Title	Protocol	PPPO	Handout
BR Breast				
UBRAJABEAI	Treatment of Adjuvant Breast Cancer using Abemaciclib and Aromatase Inhibitor With or Without LHRH Agonist	<i>Eligibility updated</i>	--	--
UBRAJABET	Treatment of Adjuvant Breast Cancer using Abemaciclib and Tamoxifen With or Without LHRH Agonist	<i>Eligibility updated</i>	--	--
BRAJLDTAM	Adjuvant Treatment of Resected Ductal Carcinoma In Situ using Tamoxifen	<i>Precautions updated</i>	--	--
BRAJLHRHT	Neoadjuvant or Adjuvant Therapy for Breast Cancer using a LHRH Agonist and Tamoxifen	<i>Tests removed and precautions updated</i>	--	--
BRAJTAM	Neoadjuvant or Adjuvant Therapy for Breast Cancer Using Tamoxifen	<i>Tests and precautions updated</i>	--	--
BRAVLHRHT	Palliative Therapy for Breast Cancer using a LHRH agonist and Tamoxifen	<i>Tests and precautions updated</i>	--	--
BRAVTAM	Palliative Therapy for Breast Cancer Using Tamoxifen	<i>Tests and precautions updated</i>	--	--
CN Neuro-Oncology				
CNETO	Palliative Treatment of Patients with Recurrent Malignant Gliomas and Ependymoma Using Low Dose Etoposide	<i>Eligibility and tests updated</i>	<i>Tests updated</i>	--
GO Gynecology				
GOOVFOLAM	Maintenance Treatment of Newly Diagnosed BRCA-Mutated Platinum Responsive Epithelial Ovarian Cancer using Olaparib	<i>Eligibility, tests, and premedications updated</i>	--	--
GOOVOLAPM	Maintenance Treatment of Relapsed, BRCA-Mutated, Platinum Sensitive and Responsive Epithelial Ovarian Cancer using Olaparib	<i>Tests and premedications updated</i>	--	--
GU Genitourinary				
UGUNMPENZ	Therapy for Non-Metastatic Castration Resistant Prostate Cancer Using Enzalutamide	--	--	<i>Side effects table and instructions for patients updated</i>
UGUPENZ	Palliative Therapy for Metastatic Castration Resistant Prostate Cancer Using Enzalutamide	--	--	<i>Side effects table and instructions for patients updated</i>

REVISED Protocols, PPPOs and Patient Handouts (*revisions in respective columns*)

Code	Protocol Title	Protocol	PPPO	Handout
LK Leukemia/BMT				
ULKCMPLP	Treatment of Chronic Myeloid Leukemia and Ph+ Acute Lymphoblastic Leukemia Using PONatinib	<i>Controlled distribution requirement removed</i>	<i>Controlled distribution requirement removed</i>	--
LY Lymphoma				
LYCODOXMR	Treatment of Burkitt Lymphoma and Leukemia (ALL-L3) with Cyclophosphamide, vinCRISTine, DOXOrubicin, Methotrexate, Leucovorin (CODOX-M) and riTUXimab	<i>Tests, supportive medications, precautions updated</i>	<i>Labs updated</i>	--
LYIT	Treatment of Lymphoma using Intrathecal Methotrexate and Cytarabine	<i>Bedrest position updated</i>	--	--
MY Myeloma				
MYDARLD	Treatment of Relapsed and Refractory Multiple Myeloma with Daratumumab in Combination with Lenalidomide and Dexamethasone With or Without Cyclophosphamide	--	<i>Typo corrected</i>	--
MYDARLDF	Treatment of Previously Untreated Multiple Myeloma and Not Eligible for Stem Cell Transplant using Daratumumab, Lenalidomide and Dexamethasone	--	<i>Typo corrected</i>	--
SM Skin and Melanoma				
SMAVDAB	Treatment of BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma Using daBRAFeinib	<i>Eligibility clarified</i>	--	--
SMAVDT	Treatment of BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma Using daBRAFeinib and Trametinib	<i>Eligibility clarified</i>	--	--
SMAVEB	Treatment of BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma using Encorafenib and Binimetinib	<i>Eligibility clarified</i>	--	--
SMAVVC	Treatment of BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma using vemURAFenib and Cobimetinib	<i>Eligibility clarified</i>	--	--
SMAVVEM	Treatment of BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma Using vemURAFenib	<i>Eligibility clarified</i>	--	--
SC Supportive Care				
SCICANS	Immune Effector Cell-Associated Neurotoxicity Syndrome Management	<i>ICANS assessment, testing and management updated</i>	<i>Tests and management updated</i>	--

Resources and Contact Information

Resource	Phone	Email / Toll Free / Fax
Systemic Therapy Update: www.bccancer.bc.ca/health-professionals/clinical-resources/systemic-therapy/systemic-therapy-update		
Systemic Therapy Update Editor	604-877-6000 x 672649	bulletin@bccancer.bc.ca
Oncology Drug Information	604-877-6275	druginfo@bccancer.bc.ca
Cancer Drug Manual Editor	250-519-5500 x 693742	nbadry@bccancer.bc.ca
Pharmacy Oncology Certification	250-712-3900 x 686820	rxchemocert@bccancer.bc.ca
Nurse Educators	604-877-6000 x 672638	nursinged@bccancer.bc.ca
CAP – Compassionate Access Program	604-877-6277	cap_bcca@bccancer.bc.ca fax 604-708-2026
OSCAR – Online System for Cancer Drugs Adjudication and Reimbursement	888-355-0355	oscar@bccancer.bc.ca fax 604-708-2051
Library/Cancer Information	604-675-8003	toll free 888-675-8001 x 8003 requests@bccancer.bc.ca
Library Document Delivery	604-675-8002	requests@bccancer.bc.ca
Pharmacy Professional Practice	604-877-6000 x 672247	mclin@bccancer.bc.ca
Professional Practice, Nursing	604-877-6000 x 672623	BCCancerPPNAdmin@ehcnet.phsa.ca
Provincial Systemic Therapy Program	604-877-6000 x 672247	mclin@bccancer.bc.ca
BC Cancer – Abbotsford	604-851-4710	toll free 877-547-3777
BC Cancer – Kelowna	250-712-3900	toll free 888-563-7773
BC Cancer – Prince George	250-645-7300	toll free 855-775-7300
BC Cancer – Surrey	604-930-2098	toll free 800-523-2885
BC Cancer – Vancouver	604-877-6000	toll free 800-663-3333
BC Cancer – Victoria	250-519-5500	toll free 800-670-3322
Community Oncology Network (CON) sites: To update your contact information, please contact: bulletin@bccancer.bc.ca		

Editorial Review Board

Mario de Lemos, PharmD, MSc(Oncol) (Interim Editor)
 Jelena Mucovic, BScPharm (Assistant Editor)
 Jeevan Dosanjh, RN, BScN

Alina Gerrie, MD, MPH, FRCPC
 Alison Pow, BScPharm